Romosozumab for treating severe osteoporosis. NICE technology appraisal guidance 791

National Institute for Health and Care Excellence (NICE)
Record ID 32018011833
English
Details
Project Status: Completed
URL for project: https://www.nice.org.uk/guidance/ta791
Year Published: 2022
URL for published report: https://www.nice.org.uk/guidance/ta791
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: England
MeSH Terms
  • Osteoporosis
  • Osteoporosis, Postmenopausal
  • Antibodies, Monoclonal
  • Bone Density Conservation Agents
Contact
Organisation Name: National Institute for Health and Care Excellence
Contact Address: Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name: nice@nice.nhs.uk
Contact Email: nice@nice.nhs.uk
Copyright: National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.